These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 23287889)

  • 1. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Bellemain-Appaix A; O'Connor SA; Silvain J; Cucherat M; Beygui F; Barthélémy O; Collet JP; Jacq L; Bernasconi F; Montalescot G;
    JAMA; 2012 Dec; 308(23):2507-16. PubMed ID: 23287889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Siller-Matula JM; Huber K; Christ G; Schrör K; Kubica J; Herkner H; Jilma B
    Heart; 2011 Jan; 97(2):98-105. PubMed ID: 20736210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis.
    Bellemain-Appaix A; Kerneis M; O'Connor SA; Silvain J; Cucherat M; Beygui F; Barthélémy O; Collet JP; Jacq L; Bernasconi F; Montalescot G;
    BMJ; 2014 Oct; 349():g6269. PubMed ID: 25954988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
    Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
    Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
    Bundhun PK; Huang F
    BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
    Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Lewis BS; Murphy SA; McCabe CH; Braunwald E;
    JAMA; 2005 Sep; 294(10):1224-32. PubMed ID: 16143698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy.
    Nairooz R; Valgimigli M; Rochlani Y; Pothineni NV; Raina S; Sardar P; Mukherjee D; Naidu SS; Shavelle DM
    Int J Cardiol; 2017 Feb; 229():82-89. PubMed ID: 27887802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
    Bossard M; Granger CB; Tanguay JF; Montalescot G; Faxon DP; Jolly SS; Widimsky P; Niemela K; Steg PG; Natarajan MK; Gao P; Fox KAA; Yusuf S; Mehta SR
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29101117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
    Feldman DN; Fakorede F; Minutello RM; Bergman G; Moussa I; Wong SC
    Am J Cardiol; 2010 Feb; 105(3):323-32. PubMed ID: 20102943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
    JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis.
    Yang J; Zeng P; Cai WY
    J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):675-680. PubMed ID: 29058279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
    Serbin MA; Guzauskas GF; Veenstra DL
    J Manag Care Spec Pharm; 2016 Aug; 22(8):939-47. PubMed ID: 27459657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.